EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials

Mariana Pierre de Barros Gomes, José Henrique Rezende Linhares iD, Tiago Pereira Dos Santos, Renata Carvalho Pereira, Renata Tourinho Santos, Stephanie Almeida da Silva, Marta Cristina de Oliveira Souza, Juliana Fernandes Amorim da Silva, Gisela Freitas Trindade, Viviane Silva Gomes, Débora Ferreira Barreto-Vieira iD, Milena Mouta Verdan França Carvalho und 11 weitere

Viruses · 2023

DOI: 10.3390/v15071486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mariana Pierre de Barros Gomes und 22 weiteren Autor:innen. Beteiligte Einrichtung: Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bio-Manguinhos/FIOCRUZ (Inovação COVID, BIO-003-FIO-20).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Successful SARS-CoV-2 inactivation allows its safe use in Biosafety Level 2 facilities, and the use of the whole viral particle helps in the development of analytical methods and a more reliable immune response, contributing to the development and improvement of in vitro and in vivo assays. In order to obtain a functional product, we evaluated several inactivation protocols and observed that 0.03% beta-propiolactone for 24 h was the best condition tested, as it promoted SARS-CoV-2 inactivation above 99.99% and no cytopathic effect was visualized after five serial passages. Moreover, RT-qPCR and transmission electron microscopy revealed that RNA quantification and viral structure integrity were preserved. The antigenicity of inactivated SARS-CoV-2 was confirmed by ELISA using different Spike-neutralizing monoclonal antibodies. K18-hACE2 mice immunized with inactivated SARS-CoV-2, formulated in AddaS03TM, presented high neutralizing antibody titers, no significant weight loss, and longer survival than controls from a lethal challenge, despite RNA detection in the oropharyngeal swab, lung, and brain. This work emphasizes the importance of using different techniques to confirm viral inactivation and avoid potentially disastrous contamination. We believe that an efficiently inactivated product can be used in several applications, including the development and improvement of molecular diagnostic kits, as an antigen for antibody production as well as a control for non-clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19MiceAnimalsAntibody FormationAntibodies, ViralImmunizationEnzyme-Linked Immunosorbent AssayAntibodies, Neutralizing

Stichwörter der Autor:innen

K18-hACE2 transgenic micePRNT50RT-qPCRSARS-CoV-2 inactivationTCID50beta-propiolactoneimmune responsenon-clinical trialsserial passages

Substanzen

Antibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Virological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
  • Viral Morphology and Morphogenesis Laboratory, Oswaldo Cruz Institute/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
  • Immunological Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
  • Pre-Clinical Trials Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
  • Recombinant Technology Laboratory, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.
  • Institute of Technology in Immunobiologicals, Bio-Manguinhos/FIOCRUZ, Rio de Janeiro 21040-900, RJ, Brazil.

ORCID-Profile: José Henrique Rezende Linhares, Débora Ferreira Barreto-Vieira, Noemi Rovaris Gardinali, Nathalia Dos Santos Alves, Luma da Cruz Moura, Patrícia Cristina da Costa Neves, Ygara da Silva Mendes, Sheila Maria Barbosa de Lima

Förderung

  • Bio-Manguinhos/FIOCRUZ (Inovação COVID, BIO-003-FIO-20)

Zitieren

APA

Gomes, M. P. B., Linhares, J. H. R., Dos Santos, T. P., Pereira, R. C., Santos, R. T., da Silva, S. A., Souza, M. C. O., da Silva, J. F. A., Trindade, G. F., Gomes, V. S., Barreto-Vieira, D. F., Carvalho, M. M. V. F., Ano Bom, A. P. D., Gardinali, N. R., Müller, R., Alves, N. D. S., Moura, L. D. C., Neves, P. C. D. C., Esteves, G. S., …, & de Lima, S. M. B. (2023). Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials. Viruses. https://doi.org/10.3390/v15071486

Vancouver

Gomes MPB, Linhares JHR, Dos Santos TP, Pereira RC, Santos RT, da Silva SA, et al. Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials. Viruses. 2023. doi:10.3390/v15071486

BibTeX
@article{Gomes2023,
  author = {Gomes, Mariana Pierre de Barros and Linhares, José Henrique Rezende and Dos Santos, Tiago Pereira and Pereira, Renata Carvalho and Santos, Renata Tourinho and da Silva, Stephanie Almeida and Souza, Marta Cristina de Oliveira and da Silva, Juliana Fernandes Amorim and Trindade, Gisela Freitas and Gomes, Viviane Silva and Barreto-Vieira, Débora Ferreira and Carvalho, Milena Mouta Verdan França and Ano Bom, Ana Paula Dinis and Gardinali, Noemi Rovaris and Müller, Rodrigo and Alves, Nathalia Dos Santos and Moura, Luma da Cruz and Neves, Patrícia Cristina da Costa and Esteves, Gabriela Santos and Schwarcz, Waleska Dias and Missailidis, Sotiris and Mendes, Ygara da Silva and de Lima, Sheila Maria Barbosa},
  title = {Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15071486}
}
Kostenlos starten →